Compare
Harrow, Inc. vs Vireo Growth Inc. vs Ligand Pharmaceuticals Inc vs Arvinas, Inc.
| Latest fiscal year | Harrow, Inc. HROW | Vireo Growth Inc. VREOF | Ligand Pharmaceuticals Inc LGND | Arvinas, Inc. ARVN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $272.30M | $268.77M | $268.09M | $262.60M |
| Revenue growth (YoY) | +36.4% | +170.4% | +60.4% | -0.3% |
| Gross margin | 75.1% | 47.3% | n/a | n/a |
| Operating margin | 11.2% | -0.4% | 15.3% | -45.1% |
| Net margin | -1.9% | -25.3% | 46.4% | -30.8% |
| Net income | -$5.14M | -$68.11M | $124.45M | -$80.80M |
| EPS (Diluted) | -$0.14 | -$0.09 | $6.13 | -$1.14 |
| Operating cash flow | $43.86M | $3.71M | $49.36M | -$273.80M |
| Free cash flow | $42.98M | -$24.61M | $48.91M | -$275.70M |
| Cash & equivalents | $72.93M | n/a | $174.93M | $142.90M |
| Total assets | $399.48M | $817.15M | $1.56B | $717.90M |
| Total liabilities | $347.39M | $509.73M | $543.42M | $284.00M |
| Shareholders' equity | $52.45M | $307.42M | $1.02B | $433.90M |
| Return on year-end equity | -9.8% | -22.2% | 12.2% | -18.6% |
| Shares outstanding | 37.23M | n/a | 19.77M | 63.50M |
Revenue, most recent five fiscal years
| Fiscal year | Harrow, Inc. | Vireo Growth Inc. | Ligand Pharmaceuticals Inc | Arvinas, Inc. |
|---|---|---|---|---|
| Latest | $272.30M Ended 2025-12-31 | $268.77M Ended 2025-12-31 | $268.09M Ended 2025-12-31 | $262.60M Ended 2025-12-31 |
| 1 year earlier | $199.61M Ended 2024-12-31 | $99.38M Ended 2024-12-31 | $167.13M Ended 2024-12-31 | $263.40M Ended 2024-12-31 |
| 2 years earlier | $130.19M Ended 2023-12-31 | $88.13M Ended 2023-12-31 | $131.31M Ended 2023-12-31 | $78.50M Ended 2023-12-31 |
| 3 years earlier | $88.59M Ended 2022-12-31 | $74.63M Ended 2022-12-31 | $196.25M Ended 2022-12-31 | $131.40M Ended 2022-12-31 |
| 4 years earlier | $72.48M Ended 2021-12-31 | $54.45M Ended 2021-12-31 | $241.54M Ended 2021-12-31 | $53.60M Ended 2021-12-31 |